Loading...

PerCP/Cyanine5.5 anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2_PerCPCyanine55_CD3_Antibody_020819_updated.png
C57BL/6 splenocytes were stained with CD45R/B220 APC and CD3 (clone 17A2) PerCP/Cyanine5.5 (left) or Rat IgG2b, κ PerCP/Cyanine5.5 isotype control (right).
  • 17A2_PerCPCyanine55_CD3_Antibody_020819_updated.png
    C57BL/6 splenocytes were stained with CD45R/B220 APC and CD3 (clone 17A2) PerCP/Cyanine5.5 (left) or Rat IgG2b, κ PerCP/Cyanine5.5 isotype control (right).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100217 25 µg 95€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100218 100 µg 259€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Marchelletta RR, et al. 2021. J Clin Invest. 131:. PubMed
  2. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  3. Wang H, et al. 2022. Immunol Cell Biol. 100:547. PubMed
  4. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  5. Rodrigues PB, et al. 2022. Cells. 11: . PubMed
  6. Chen X, et al. 2022. J Extracell Vesicles. 11:e12279. PubMed
  7. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
  8. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  9. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  10. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  11. Cui B, et al. 2023. Int Immunopharmacol. 114:109541. PubMed
  12. Tunali G, et al. 2023. J Clin Invest. :. PubMed
  13. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  14. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  15. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  16. Chen Y, et al. 2020. Virol Sin. . PubMed
  17. Abraham A, et al. 2019. J Clin Invest. 130:2685. PubMed
  18. Li SX, et al. 2019. PLoS Pathog. 15:e1007611. PubMed
  19. Kawabe T, et al. 2020. Nat Commun. 2.795833333. PubMed
  20. Alghamri MS, et al. 2022. ACS Nano. 16:8729. PubMed
  21. Lin J, et al. 2022. Adv Sci (Weinh). 9:e2202633. PubMed
  22. Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed
  23. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  24. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  25. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  26. Wang Y, et al. 2023. EBioMedicine. 90:104480. PubMed
  27. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  28. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  29. Wiedmann L, et al. 2023. Nat Commun. 14:2353. PubMed
  30. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  31. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  32. Tsugawa H, et al. 2023. PLoS Pathog. 19:e1011139. PubMed
  33. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  34. Zhou M, et al. 2023. Nat Commun. 14:3593. PubMed
  35. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  36. Guo X, et al. 2023. Mol Immunol. 160:32. PubMed
  37. Ye Y, et al. 2022. Nat Commun. 13:6458. PubMed
  38. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  39. McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed
  40. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  41. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  42. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  43. Pessoa Rodrigues C, et al. 2021. Sci Adv. 7:. PubMed
  44. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  45. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  46. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  47. Zhang S, et al. 2021. Cell. 184(8):2151-2166.e16. PubMed
  48. Eastman A, et al. 2016. J Immunol . 194: 5999-6010. PubMed
  49. Molofsky A, et al. 2013. J Exp Med. 210:535. PubMed
  50. Han Y, et al. 2020. Nat Commun. 11:1776. PubMed
  51. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  52. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  53. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  54. Yang F, et al. 2020. Cancer Res. 80:3677. PubMed
  55. Burrack KS et al. 2018. Immunity. 48(4):760-772 . PubMed
  56. Jin Q, et al. 2022. Drug Des Devel Ther. 16:3297. PubMed
  57. Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed
  58. Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed
  59. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  60. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  61. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  62. Chakraborty S, et al. 2022. Sci Transl Med. . PubMed
  63. Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed
  64. Domingos-Pereira S, et al. 2019. Cancer Immunol Res. 7:621. PubMed
  65. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  66. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  67. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  68. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  69. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  70. Mamedov MR, et al. 2018. Immunity. 48:350. PubMed
  71. Soutto M, et al. 2017. J Cancer. 8:2424. PubMed
  72. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
  73. Ercoli G, et al. 2022. Clin Transl Immunology. 11:e1366. PubMed
  74. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  75. Vettorazzi S, et al. 2015. Nat Commun. 6: 7796. PubMed
  76. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  77. Fu Z, et al. 2021. Cell Res. 31:631. PubMed
  78. Colombo M, et al. 2022. iScience. 25:105042. PubMed
  79. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  80. Andrade ACDSP, et al. 2021. J Virol. 95:e0127621. PubMed
  81. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  82. Chatterjee D, et al. 2021. Cell Reports. 35(2):108996. PubMed
  83. Ballesteros I, et al. 2020. Cell. 183(5):1282-1297.e18. PubMed
  84. Tian Y, et al. 2016. J Immunol. 197: 1308 - 1321. PubMed
  85. Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed
  86. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  87. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  88. Agarwal P, et al. 2019. Cell Stem Cell. 24:769. PubMed
  89. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  90. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  91. Niderla-Bielinska J, et al. 2021. Int J Mol Sci. :22. PubMed
  92. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  93. Al-Barwani F, et al. 2014. PLoS One. 9:104523. PubMed
  94. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  95. Bennett FC, et al. 2018. Neuron. 98:1170. PubMed
  96. Shehata L, et al. 2019. Cell Rep. 28:3300. PubMed
  97. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  98. Reda M, et al. 2022. Nat Commun. 13:4261. PubMed
  99. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  100. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  101. Laubreton D, et al. 2020. Viruses. 12:00. PubMed
  102. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  103. Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed
  104. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  105. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  106. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  107. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  108. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  109. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  110. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  111. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  112. Jiang Y, et al. 2015. MBio. 6: e01426-15. PubMed
  113. Agarwal P, et al. 2021. Cell Reports. 36(2):109386. PubMed
  114. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  115. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  116. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  117. Chirivi RGS, et al. 2020. Cell Mol Immunol. . PubMed
  118. Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed
  119. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  120. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
RRID
AB_1595492 (BioLegend Cat. No. 100217)
AB_1595492 (BioLegend Cat. No. 100218)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD3 Reagents Request Custom Conjugation
Description Clone Applications
FITC anti-mouse CD3 17A2 FC
PE anti-mouse CD3 17A2 FC
Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Alexa Fluor® 647 anti-mouse CD3 17A2 FC,IHC-F,3D IHC,SB
Alexa Fluor® 488 anti-mouse CD3 17A2 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD3 17A2 FC
Alexa Fluor® 700 anti-mouse CD3 17A2 FC
PerCP/Cyanine5.5 anti-mouse CD3 17A2 FC
PE/Cyanine7 anti-mouse CD3 17A2 FC
APC/Cyanine7 anti-mouse CD3 17A2 FC
Brilliant Violet 421™ anti-mouse CD3 17A2 FC,ICC
Brilliant Violet 570™ anti-mouse CD3 17A2 FC
Brilliant Violet 650™ anti-mouse CD3 17A2 FC
Brilliant Violet 785™ anti-mouse CD3 17A2 FC
Brilliant Violet 510™ anti-mouse CD3 17A2 FC
APC anti-mouse CD3 17A2 FC
Ultra-LEAF™ Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Brilliant Violet 605™ anti-mouse CD3 17A2 FC
Alexa Fluor® 594 anti-mouse CD3 17A2 IHC-F,FC,3D IHC,SB
Brilliant Violet 711™ anti-mouse CD3 17A2 FC
Biotin anti-mouse CD3 17A2 FC,IHC-F
PE/Dazzle™ 594 anti-mouse CD3 17A2 FC
APC/Fire™ 750 anti-mouse CD3 17A2 FC
Brilliant Violet 750™ anti-mouse CD3 17A2 FC
TotalSeq™-A0182 anti-mouse CD3 17A2 PG
TotalSeq™-B0182 anti-mouse CD3 17A2 PG
Spark Blue™ 550 anti-mouse CD3 17A2 FC
Spark NIR™ 685 anti-mouse CD3 17A2 FC
TotalSeq™-C0182 anti-mouse CD3 17A2 PG
APC/Fire™ 810 anti-mouse CD3 17A2 FC
PE/Fire™ 640 anti-mouse CD3 17A2 FC
Spark YG™ 570 anti-mouse CD3 17A2 IHC-F
PE/Fire™ 700 anti-mouse CD3 17A2 FC
PE/Cyanine5 anti-mouse CD3 17A2 FC
Spark Blue™ 574 anti-mouse CD3 Antibody 17A2 FC
Spark Violet™ 423 anti-mouse CD3 17A2 FC
PE/Fire™ 810 anti-mouse CD3 17A2 FC
Spark Red™ 718 anti-mouse CD3 17A2 FC
Spark UV™ 387 anti-mouse CD3 17A2 FC
Go To Top Version: 3    Revision Date: 02/08/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account